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Background:Meta-analyses of observational studies associate adherence to several dietary patterns with cog-
nitive health. However, limited evidence from full scale, randomized controlled trials precludes causal infer-
ence regarding dietary effects on cognitive function.
Methods: The Women’s Health Initiative (WHI) Dietary Modification (DM) randomized trial, in 48,835 post-
menopausal women, included a subset of 1,606 WHI Memory Study (WHIMS) participants >= 65 years old,
to assess low-fat dietary pattern influence on global cognitive function, evaluated with annual screening
(Modified MiniMental State Examinations [3MSE]). Participants were randomized by a computerized, per-
muted block algorithm, stratified by age group and center, to a dietary intervention (40%) to reduce fat intake
to 20% of energy and increase fruit, vegetable and grain intake or usual diet comparison groups (60%). The
study outcome was possible cognition impairment (failed cognitive function screening) through the 8.5 year
(median) dietary intervention. Those failing screening received a comprehensive, multi-phase cognitive
function assessment to classify as: no cognitive impairment, mild cognitive impairment, or probable demen-
tia. Exploratory analyses examined the composite endpoint of death after possible cognitive impairment
through 18.7 years (median) follow-up. The WHI trials are registered at ClinicalTrials.gov:NCT00000611.
Findings: Among the 1,606 WHIMS participants, the dietary intervention statistically significantly reduced
the incidence of possible cognitive impairment (n = 126; hazard ratio [HR] 0.59 95% confidence interval [CI]
0.380. 91, P = 0.01) with HR for dietary influence on subsequent mild cognitive impairment of 0.65 (95% CI
0.351.19) and HR of 0.63 (95% CI 0.192.10) for probable dementia (PD). Through 18.7 years, deaths from
all-causes after possible cognitive impairment were non-significantly lower in the dietary intervention group
(0.56% vs 0.77%, HR 0.83 95% CI 0.35 to 2.00, P = 0.16).
Interpretation: Adoption of a low-fat eating pattern, representing dietary moderation, significantly reduced
risk of possible cognitive impairment in postmenopausal women.
Funding: Several Institutes of the US National Institutes of Health.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
Cognition
Dietary modification
Low-fat dietary pattern
Randomized clinical trial
Women’s Health Initiativehlebowski).
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Evidence before this study
Cognitive dysfunction and dementia represent major health
risks in women as they age. Observational studies have associ-
ated several dietary patterns with cognitive health. However,
few randomized trials have evaluated dietary influence on cog-
nition. The 2010 NIH Report on Preventing Alzheimer’s Disease
and Cognitive Decline noted a critical need for randomized tri-
als in this area and proposed criteria for such trials. To our
review, the four trials meeting these criteria have limitations of
short intervention durations and absence of long term follow-
up. Against this background, we provide findings from a large
(n = 1606) subgroup of postmenopausal women participating
in the Women’s Health Initiative (WH)I Memory Study
(WHIMS) who were among the 48,835 women in the WHI Die-
tary Modification (DM) trial evaluating the potential influence
of a low-fat dietary pattern on cognitive impairment.
Added value of this study
WHIMS participants, between 65 and 79 years old, were ran-
domized to dietary intervention with a target of fat intake
reduction and increase in fruits, vegetables and grains or usual
diet comparison groups. Annual cognitive function screening
through 8.5 years (median) intervention was based on Modified
Mini-Mental Examinations [3MSE]. The study endpoint was
possible cognitive impairment (failed 3MSE screening). Those
with failed screening received a comprehensive, multi-phase
neuropsychological evaluation and were followed for clinical
outcome. In contrast to the comparison group, women in the
dietary intervention group had a significantly decreased risk of
possible cognitive impairment (hazard ratio [HR] 0.59 95% con-
fidence interval [CI] 0.380.91, P = 0.01). Through 18.7 years,
deaths from all-causes after possible cognitive impairment
were non-significantly lower in the dietary intervention group
(0.56% vs 0.77%, HR 0.83 95% CI 0.35 to 2.00, P = 0.16).
Implications of the available evidence
Our current findings provide prospective, randomized clinical
trial evidence that adoption of a low-fat dietary pattern, repre-
senting dietary moderation, significantly reduced risk of possi-
ble cognitive impairment in postmenopausal women. Our
study design, duration of the dietary intervention and length of
follow-up, substantially strengthens evidence that a dietary
pattern can influence cognitive function and identifies fat
intake reduction as a component of the dietary pattern.
1. Introduction
Late-age development of cognitive impairment and dementia rep-
resent major health risks, especially in women where about two
thirds of cases are seen [1]. The World Health Organization (WHO)
and others have emphasized the importance of development of pre-
vention strategies to most effectively address this problem [2,3]
while noting the critical need for randomized clinical trial evidence
in this area [4,5].
The potential association between various components of diet and
cognitive function have been of interest [6]. In pre-clinical models,
high-fat diets have hindered rodent memory performance and
injured hippocampal neurons [7,8]. High-energy and high fat intakehas been associated with cognitive deficits and dementia in some,
but not all, observational studies [912]. However, a recent meta-
analysis of prospective cohort studies found significant evidence of
positive association between higher saturated fat intake and demen-
tia risk [12]. The influence of a low-fat dietary pattern on global cog-
nitive function has not previously been evaluated in a full scale, long
term, randomized clinical trial setting.
The WHI DM trial provides an opportunity to evaluate whether a
low-fat dietary pattern influences global cognitive function in a ran-
domized, controlled clinical trial setting in a subset of 1606 study
participants also enrolled in the Women’s Health Initiative Memory
Study (WHIMS) [13], where annual assessment of global cognitive
assessment was performed through 8.5 years of the dietary interven-
tion. Exploratory analyses examine subsequent risk of possible cogni-
tive impairment followed by mortality (composite outcome) after
cumulative 18.7 years (median) follow-up in WHIMS participants
2. Methods
Design details of the WHI DM trial have been described [14]. In
the trial, 48,835 postmenopausal women between 50 and 79 years of
age, were randomly assigned from 1993 to1998, to a dietary inter-
vention group (40%; n = 19,541) designed to implement a low-fat die-
tary pattern with the primary goal of reducing dietary fat intake to
20% of energy while increasing intake of fruits, vegetables and grains
or to a usual diet comparison group (60%; n = 29,294) [15]. Randomi-
zation was conducted at the WHI Clinical Coordinating Center. The
protocol-specified co-primary endpoints were invasive breast cancer
and colorectal cancer. Of these, 1606 study participants were also
enrolled in WHIMS [13], an ancillary study to the two WHI clinical
trials evaluating hormone therapy [14] where annual assessment of
global cognitive function was performed during the 8.5 year (median)
dietary intervention period. The WHI trials are registered at Clinical-
Trials.gov:NCT00000611. Institutional Review Board (IRB) approval
for each trial component was obtained at all the clinical centres and
all participants provided written informed consent. The WHI Project
Office at the US National Heart, Lung, and Blood Institute (NHLBI), the
sponsor of this project, had no role in the preparation of this report.
For WHIMS participation, women had to be active in one of the
WHI hormone therapy trials assessing estrogen plus progestin or
estrogen alone, be 65 to 79 years of age, free of dementia, willing to
undergo annual cognitive assessments, and willing to identify a
friend or family member who could provide information about her
functioning.
Between 1996 and 2007, WHIMS participants were tested at
enrollment and annually thereafter by centrally trained, certified
examiners, blinded to randomization status, for global cognitive func-
tioning using the Modified MiniMental State Examination (3MSE)
[16]. A detailed description of the WHIMS comprehensive multi-
phase protocol for detecting probable dementia and mild cognitive
impairment has been published [13]. Briefly, the test items measured
temporal and spatial orientation, immediate and delayed recall, exec-
utive function, abstract reasoning, praxis, writing, and visuoconstruc-
tional abilities (copying). The 3MSE has demonstrated good
sensitivity and specificity for detecting cognitive impairment [17,18].
After initial cognitive screening with the 3MSE, women that scored
below an education-adjusted cut point [16,19] were identified as
having possible cognitive impairment (considered as being cogni-
tively vulnerable). Prior study has demonstrated ability of such
screening tools to identify individuals with cognitive impairment
[20].
Those with possible cognitive impairment received a comprehensive
multi-phase evaluation which included administration of a comprehen-
sive and validated neuropsychological battery [21], questionnaires
regarding acquired cognitive and behavioral deficits and neuropsychiat-
ric symptoms [22] and standardized neuropsychiatric evaluation by
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or psychiatrists), who then reviewed this information and classified the
women into one of three categories  no cognitive impairment, mild
cognitive impairment or probable dementia [19,23]. For those classified
as probable dementia, brain computed tomography and laboratory
blood tests were used to rule out possible reversible causes. Final study
classification of mild cognitive impairment or probable dementia was
adjudicated at theWHIMS Clinical Coordinating Center at theWake For-
est University School of Medicine by a panel of dementia experts that
included two neurologists, a geriatric psychiatrist and a geriatric psy-
chologist. A supplemental case ascertainment protocol was developed
and used to ascertain outcomes for deceased and/or proxy- dependent
participants [24].
Dietary intervention group sessions were led by specially trained
and certified nutritionists with 18 group sessions in year one and
subsequent quarterly maintenance group sessions throughout the
8.5 year (median) dietary intervention period. Subsequently, all con-
tact with study nutritionists ended as post-intervention follow-up
began. During the intervention period, the percent reduction in
energy from fat (810% decrease) and the increase in servings of
fruits and vegetables and servings of grain were all statistically signif-
icant (P< 0.001) [15]. Although caloric restriction or weight loss were
not intervention targets, an early statistically significant weight loss
(3%) emerged in the intervention group.
The primary study analysis was dietary modification influence on
global cognitive function (failed cognitive function screening as pos-
sible cognitive impairment) in WHIMS participants through the pro-
tocol defined 8.5 year dietary intervention period. Also, in an
exploratory analysis, we examined deaths from all-causes after possi-
ble cognitive impairment in WHIMS participants through 18.7 years
(median) cumulative follow-up.
Cumulative follow-up (intervention plus post-intervention phases)
included deaths through December 31, 2016 (median [Q1-Q3], 18.7
[14.619.5] years cumulatively) with mortality ascertained by regular
surveillance of the cohort with deaths documented by through the
National Death Index (NDI) and by Information reports of next of kin or
the postal service. NDI searches were conducted at nine time points
before 2018 for all participants with unknown vital status.
2.1. Statistical analysis
The current study analyses were not protocol pre-specified. The
primary endpoint of possible cognitive impairment and the explor-
atory composite endpoint of death from all causes after possible cog-
nitive impairment in WHIMS participants were assessed by
randomly assigned DM intervention group by dividing the number of
events by the corresponding person-time elapsed from randomiza-
tion in each period. HRs contrasting the intervention and comparison
groups by diagnosis of possible cognitive impairment (no cognitive
impairment/mild cognitive impairment/probable dementia) were
estimated using competing risk models that included cause-specific
baseline hazard functions and hazard ratios [25]. Cumulative hazard
curves were generated, and HRs and 95% CIs and P values computed
using Cox regression models stratified on age group in 5-year catego-
ries, race/ethnicity, education, and randomization status in the WHI
hormone therapy trials. The endpoint of possible cognitive
impairment was assessed through 8.5 years follow-up during the die-
tary intervention period when annual assessment of global cognitive
function was available. WHIMS participants contributed follow-up
time until the end of DM intervention phase, date of possible cogni-
tive impairment, loss to follow-up, or death, whichever came first.
The composite endpoint of death after possible cognitive impairment
was assessed from randomization through the available 18.7 year
(median) follow-up period, where participants without possible cog-
nitive impairment were censored at the end of the intervention
phase or death (whichever came first), since they were no longer atrisk for the composite endpoint, while those with an impairment
contributed follow-up time until death or December 31, 2016 (Fig. 1),
the last date covered by the NDI linkage. This type of composite end-
point has been used elsewhere in the context of breast cancer pro-
gression [2628], described thoroughly [29], utilize usual indicator
variables for event status (1 = time to composite event was observed;
0 = observation was censored), and can be fit with the usual Cox
regression software implementations.
All statistical tests are 2-sided and nominal P values of 0.05 or less
are regarded as statistically significant. P-values do not adjust for
multiple outcomes. All statistical analyses were conducted using SAS
software version 9.4 (SAS Institute Inc.) and R software version
3.4 (R Foundation for Statistical Computing). As dietary interven-
tion effects were examined in 11 subgroup analyses, less than
one statistically significant interaction was expected by chance
alone ( 11 £ 0.05) [30].
3. Results
Baseline characteristics of WHIMS participants, including demo-
graphic, medical history, and dietary variables were well balanced
between randomization groups (Table 1). Briefly, women were, on
average, 69.9 years of age, somewhat overweight with median BMI of
29.5 kg/m2 and 29% had a college degree or higher. Characteristics
associated with risk of cognitive impairment and dementia including
age, education, smoking status, stroke history, diabetes, hormone
use, waist circumference, blood pressure, body mass index, and aspi-
rin use were also well-balanced between the two groups. Participant
flow through cumulative follow-up is outlined in Fig. 1. After one
year of dietary intervention, changes in the 1606 participants with
cognitive function assessment reflected findings in the overall group,
namely statistically significant reduction in percent calories fat, and
increasing from and vegetable intake and, although not protocol tar-
get decreased weight and waist circumference (Table 2).
At entry, the distribution of baseline 3MSE scores (0 worst to 100
best) was notably left (negative)-skewed with median (Q1-Q3) = 96.0
(94.0, 98.0), but well balanced between groups. During median (Q1-
Q3) follow-up of 7.2 (6.08 0) years following WHIMS enrollment,
while annual global cognitive function assessment was ongoing dur-
ing the dietary intervention period, there were 126 incident cases of
possible cognitive impairment identified with 41 (0.94%) in the inter-
vention group and 85 (1.37%) in the comparison group; the dietary
intervention resulted in a statistically significant reduction in the
incidence of possible cognitive impairment with a HR 0.59 (95%CI
0.380.91, P = 0.01) (Fig. 2).
Kaplan-Meier estimates of the cumulative hazard curves for possi-
ble cognitive impairment during the intervention period are depicted
in Fig. 3. As seen, in the comparison group, there is a year-to-year
increase in the risk of exceeding the target threshold for cognitive
performance in 3MSE resulting in a designation of possible cognitive
impairment of about 1.5% per year, with early separation (by year 2)
with lower risk seen in the intervention group. Of the 126 partici-
pants identified with possible cognitive function impairment, after
further comprehensive neurological assessment, 59% were catego-
rized as having mild cognitive impairment or probable dementia; for
findings in the dietary intervention versus comparison groups, HR
was 0.65 (95% CI 0.351.19) for mild cognitive impairment and HR of
0.63 (95% CI 0.192.10) for probable dementia (bottom panel of
Fig. 2) while the remaining women were categorized as having no
cognitive impairment. Combining confirmation of mild cognitive
impairment or probable dementia (27 v 47 events) yields an HR of
0.65 (95%CI 0.381.11).
The dietary influence on possible cognitive impairment was most
evident among women in the lowest quartile of 3MSE score at
WHIMS enrollment, identifying those with lower global cognitive
function (HR 0.43 95% CI 0.220.84) as the influence diminished with
Fig. 1. Participant flow diagram for the low-fat dietary intervention phase among the subset of DM trial participants that participated in WHIMS (n = 1606), an age eligible
subset (age  65 years) of the WHI MHT trials. WHIMS = Women’s Health Initiative Memory Study; MHT = menopausal hormone therapy; CEE = conjugated equine estrogen;
MPA = medroxyprogesterone acetate.
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explored further by assessing the dietary influence on year-to-year
mean change in 3MSE score as a measure of global cognitive function
stratified by baseline 3MSE quartiles. Although the overall influ-
ence of the dietary intervention on 3MSE change score was not
significant, mean (95% CI) = 0.1 (0.2 to 0.4) with P = 0.47, there
was a significant interaction between randomization group and
baseline 3MSE score (quartile; P = 0.02, based on test of linear-
trend of group means (Supplemental Figure). Specifically, dietaryintervention resulted in an increase in 3MSE score beginning in
year two among women with low baseline 3MSE score corrobo-
rating the favorable effect of dietary intervention seen on possible
cognitive impairment in the same low 3MSE score subgroup;
mean change score during follow-up was mean (95% CI) = 0.7(0.1
to 1.3). In contrast, the mean change scores for increasing quar-
tiles did not suggest a difference; mean (95% CI) = 0.2(0.5, 0.9),
0.3(0.9, 0.3) and 0.04(0.5, 0.4), respectively. Suggestions of
a heterogeneous influence for diet was not observed in any of the
Table 1
Baseline characteristics of DM trial participants that participated in WHIMS
(n = 1606).
No. and% of Participants1
Intervention (N = 652) Comparison (N = 954)
Characteristic
Age at screening (y), mean,
SD
69.9 3.7 69.9 3.6
Age group at screening, y
6069 343 52.6 501 52.5
7079 309 47.4 453 47.5
Race/ethnicity
White 557 85.4 819 85.8
Black 53 8.1 90 9.4
Hispanic 25 3.8 20 2.1
American Indian 0 0.0 3 0.3
Asian/Pacific Islander 6 0.9 10 1.0
Unknown 11 1.7 12 1.3
Education
< High school 51 7.8 67 7.0
High school diploma/GED 134 20.6 221 23.2
School after high school 266 40.8 400 41.9
College degree or higher 201 30.8 266 27.9
Smoking
Never 346 53.9 540 57.1
Past 254 39.6 354 37.5
Current 42 6.5 51 5.4
Stroke 9 1.4 18 1.9
Diabetes 61 9.4 93 9.7
Hormone use
Never 437 67.0 662 69.4
Past 169 25.9 233 24.4
Current 46 7.1 59 6.2
Waist circumference (cm),
mean, SD
92.0 13.2 92.7 13.0
Systolic BP (mm Hg), mean,
SD
132.8 17.3 133.3 17.9
Diastolic BP (mm Hg), mean,
SD
75.3 9.0 76.0 8.9
Body mass index2, median
(Q1-Q3), IQR
29.3 25.733.4 29.8 26.333.8
3MSE score, median
(Q1-Q3), IQR
96.0 94.098.0 96.0 93.098.0
Hypertensive (Self-report or
high BP)
329 50.6 538 56.7
Aspirin use ( 80 mg for 30
days)
136 20.9 233 24.4
MHT randomization group
CEE-alone 119 18.3 218 22.9
CEE-alone placebo 126 19.3 218 22.9
CEE+MPA 188 28.8 265 27.8
CEE+MPA placebo 219 33.6 253 26.5
Percent energy from total
fat (%), mean, SD
37.8 5.0 38.3 5.3
Percent energy from pro-
tein (%), mean, SD
16.4 3.0 16.5 3.0
Percent energy from car-
bohydrates (%), mean, SD
45.9 6.3 45.1 6.4
Fruit and vegetable intake
(med serv/day), mean, SD
3.8 2.0 3.7 1.9
1 Values are reported as No. and% unless otherwise indicated.
2 Calculated as weight in kilograms divided by height in meters squared.
Table 2
Change characteristics of DM trial participants that participated in WHIMS (n = 1606).
Intervention (N = 652) Comparison (N = 954)
Post-randomization
variables
Mean SD Mean SD P-Value
Change in percent energy from:
Total fat (%) 12.3 7.8 1.6 6.2 <0.001
Saturated fat (%) 4.3 3.3 0.6 2.6 <0.001
Polyunsaturated fat (%) 2.3 2.1 0.2 2.1 <0.001
Monounsaturated fat (%) 4.9 3.3 0.6 2.8 <0.001
Trans-fat (%) 1.0 1.2 0.1 1.2 <0.001
Carbohydrates (%) 11.7 9.0 1.6 6.9 <0.001
Protein (%) 1.3 3.2 0.1 2.9 <0.001
Animal protein (%) 0.3 3.6 0.0 3.1 0.12
Vegetable protein (%) 1.0 1.2 0.1 1.0 <0.001
Alcohol (%) 0.1 2.4 0.1 2.1 0.83
Change in other dietary characteristics:
Vegetable and fruit (med
serv/day)
1.3 2.3 0.2 1.8 <0.001
Grains (med serv/day) 0.0 2.6 0.6 2.3 <0.001
Dietary fiber (g) 2.2 6.9 0.5 5.7 <0.001
Cholesterol (mg) 92.1 147.7 26.5 132.4 <0.001
Change in participant characteristics:
Weight (kg) 2.1 11.9 0.1 10.0 <0.001
Waist (cm) 1.7 5.8 0.4 6.1 <0.001
Systolic BP (mm Hg) 3.6 15.0 2.1 17.7 0.10
Diastolic BP (mm Hg) 2.8 8.7 2.0 9.2 0.07
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interactions were statistically significant.
The clinical significance of screening positive for possible cogni-
tive impairment was examined for subsequent mortality risk (death
from all causes) through 18.7 years median follow-up by cognitive
function category: normal (never failed 3MSE screening, n = 1480),
no cognitive impairment (but failed screening as possible cognitive
impairment, n = 52); mild cognitive impairment (n = 57); and proba-
ble dementia (n = 17). Subsequent mortality by group was 46%, 58%,
61%, and 100%, respectively. Thus, the designation of possible cogni-
tive impairment likely identifies a population of clinical relevance.Exploratory analyses found deaths from all-causes after possible cog-
nitive impairment was non-significantly lower for the intervention
versus comparison group (0.56% vs 0.77%, HR 0.83 95% CI 0.35 to
2.00, P = 0.16).
4. Discussion
In theWHI Dietary Modification randomized clinical trial evaluating
a low-fat dietary pattern, in a subgroup of 1606 postmenopausal
women also enrolled in the WHI Memory Study (WHIMS) having
annual assessment of global cognitive function, adoption of a low-fat
dietary pattern significantly reduced the risk of possible cognitive
impairment based on the findings from serial 3MSE results. Subsequent
neurological assessment of those with possible cognitive impairment
diagnosed 59% with either mild cognitive impairment (45%) or proba-
ble dementia (14%). As exploratory analyses were suggestive of a higher
mortality risk in women with possible cognitive impairment, even in
the absence of mild cognitive impairment or probable dementia, com-
pared to women without such findings, those failing 3MSE screening
likely identifies a population of clinical relevance.
The significant reduction in possible cognitive impairment (HR
0.59 95% CI 0.380.91, P = 0.01) in the dietary intervention group
was followed by a smaller non-significant reduction in deaths after
possible impairment (HR = 0.83), suggest that a post-impairment sur-
vival benefit is unlikely [29]. These results are consistent with the
hypothesis offered by Feart and colleagues [31] in response to their
cohort study finding that higher Mediterranean diet adherence was
associated with slower cognitive decline but not with dementia. They
suggested that the Mediterranean diet may have a beneficial effect
during the prodromal phase of dementia, rather than the last few
years preceding diagnosis, after which pathophysiological processes
cannot be reversed by diet. Such findings suggest lifestyle interven-
tions may have most effect when begun by individuals without cog-
nitive impairment.
The favorable dietary effect of reducing the incidence of possible
cognitive impairment was greater in women with lower, less favor-
able, baseline 3MSE scores, a finding supported by serial year-to-year
analyses of global cognitive function where a statistically significant
interaction suggests more favorable diet effect in the group with
Fig. 2. Overall influence of the low-fat dietary intervention on possible cognitive impairment* during the intervention phase among the subset of DM trial participants that
participated in WHIMS (n = 1606). The 7-year follow-up is over the dietary intervention phase of the trial (median, 7.2 [interquartile range {IQR}, 6.08.0] years). Summary statis-
tics computed from Cox regression models stratified by 5-year age group, race/ethnicity, education, and randomization status in the WHI hormone therapy trials, using time from
randomization as the time-scale. Subgroups were investigated, one at a time, by including an interaction term between randomization arm and subgroup with additional stratifica-
tion of the baseline hazard by corresponding subgroup. P values corresponds to a two-sided score (log-rank) test of the dietary intervention’s overall influence, or for the subgroup
analysis, a test of interaction between the randomization group and corresponding subgroup. Percentages are annualized. * Possible cognitive impairment defined as transition to
Phase 2 of the WHIMS protocol. After completion of Phases 2 and 3, typically within 3 months possible cognitive impairment, participants were classified as probable dementia,
mild cognitive impairment, or no cognitive impairment. y Ever used menopausal hormone therapy or randomized to CEE or CEE+MPA arm of WHI hormone trial. ^ Among women
randomized to either WHI hormone therapy trial. WHIMS =Women’s Health Initiative Memory Study; HR = hazard ratio; CI = confidence interval.
6 R.T. Chlebowski et al. / EClinicalMedicine 18 (2020) 100240lowest baseline 3MSE scores. Comparatively less favorable results
among women having higher baseline 3MSE scores may represent a
limitation of the 3MSE assessment. For example, the top quartile ofwomen have scores  98 leaving little/no room for improvement
against an upper 3MSE score limit of 100. Subgroup analyses should
be interpreted with caution because of multiple comparisons.
Fig. 3. Kaplan-Meier estimates of the cumulative hazard for possible cognitive
impairment* during the intervention phase among the subset of DM trial partici-
pants that participated in WHIMS (n = 1606). The 7-year follow-up is over the dietary
intervention phase of the trial (median, 7.2 [interquartile range {IQR}, 6.08.0] years).
Summary statistics computed from a Cox regression model stratified by 5-year age
group, race/ethnicity, education, and randomization status in the WHI hormone ther-
apy trials, using time from randomization as the time-scale. P-value corresponds to a
two-sided score (log-rank) test of the dietary intervention’s overall influence. Percen-
tages are annualized. * Possible cognitive impairment defined as transition to Phase 2
of the WHIMS protocol. After completion of Phases 2 and 3, typically within 3 months
of possible cognitive impairment, participants were classified as probable dementia,
mild cognitive impairment, or no cognitive impairment. WHIMS = Women’s Health
Initiative Memory Study; HR = hazard ratio; CI = confidence interval.
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adherence to the Mediterranean, Dietary Approaches to Stop Hyper-
tension (DASH), and Mediterranean -DASH Intervention for Neuro-
degenerative Delay (MIND) diets with less cognitive decline [32,33].
However, few randomized trials have evaluated nutrition based
interventions in relation to cognition and most have been limited in
size and duration [6].
The 2010 National Institutes of Health Evidence Report on Pre-
venting Alzheimer’s Disease and Cognitive Decline [34] proposed cri-
teria for future randomized clinical trials which included
intervention duration of at least one year and size of 500 partici-
pants. Using these criteria, we identified four prior randomized trials
assessing a dietary intervention with or without other intervention
components with design and findings outlined in Table 3. Three
[3537] of four trials entered participants with cognitive dysfunction
or those at high risk for cognitive dysfunction or vascular disease.
Intervention durations were 1 year [38], 2 years [36], 3 years [37] and
6.5 years [35]. Each of the four trials used different cognitive function
endpoints. All presented baseline and final endpoint assessmentsprecluding determination of trajectory of cognitive dysfunction over
time. None of the trials evaluated a low-fat eating pattern.
Two of the four trials had positive findings. The FINish GERiatric
Intervention Study (FINGER) was a mutidomain intervention (diet,
exercise, cognitive training, and vascular risk monitoring) involving
1260 participants. The dietary component included recommenda-
tions for 1020% of energy from protein, 2535% of energy from fat
with targets for specific fat types and energy intake reduction facili-
tating 510% body weight reduction if needed. The intervention
resulted in improved or maintained cognition over the two year
study duration [36]. The second study with positive findings presents
a subsample report from one of 12 recruitment centres of the PRE-
vencion con Dieta MEDiterranea (PREDIMED) where effects of a Med-
iterranean diet influence on cognitive function diet was assessed
against a “low fat” control diet with 522 participants randomized
across three interventions. As no decrease in dietary fat intake was
reported in the “low fat” group, PREDIMED operationally had a usual
diet control. In any event, a Mediterranean diet enhanced with either
extra-virgin olive oil or nuts appeared to improve cognition com-
pared to the control condition [35]. Of these larger randomized trials,
three of four entered participants at cognitive function risk while
three of four reported findings after interventions of three years or
less.
The current report adds to the emerging evidence that dietary
intake can influence cognitive function in a randomized trial involv-
ing relatively healthy postmenopausal women not selected for cogni-
tive risk and followed over a long period. In this setting, findings
from the WHI DM trial indicate that dietary fat intake reduction may
also be a factor to be incorporated in future dietary recommenda-
tions.
The WHI DM low-fat dietary plan is somewhat similar to the Die-
tary Approach to Stopping Hypertension (DASH) which includes rec-
ommendations to increase fruits, vegetables and grains, use no/low
fat dairy products, and reduce total fat intake [39]. While the WHI
DM low-fat dietary plan does provide more emphasis on total fat
reduction than DASH, it can still be best described as one of dietary
moderation not requiring extreme change.
The WHI DM finding of a favorable effect of a low- fat dietary pat-
tern on possible cognitive impairment is also similar in many
respects to, and supportive of, the most recent World Health Organi-
zation (WHO) Guidelines for Risk reduction of Cognitive Decline and
Dementia [40]. Their recommendation for a healthy diet includes five
portions of fruits, vegetables and whole grains a day and less than
30% of total energy intake from fats. Additionally, the guideline spe-
cifically recommends the Mediterranean diet as “more effective than
usual care in reducing risk/progression of cognitive decline and/or
dementia” [40].
The dietary changes of the WHIMS subset in the dietary interven-
tion reflect those achieved by women in the entire dietary interven-
tion group. After one year, the percent energy from fat was 24.3%
(mean [SD] 7.5%) [15] and remained statistically significantly differ-
ent than the control group throughout the 8.5 year intervention
where, at final assessment, level was 29.8% [8.3] [41]. These levels are
not much different from the average US intake of postmenopausal
women of 33%. While statistically significant, the increase in fruit and
vegetable intake was modest with an increase from about four to five
servings per day for each and achieved WHO nutritional recommen-
dations. Although not an intervention target, a statistically significant
weight loss difference of between 1.9 to 0.4 kg, compared to the con-
trol group, was maintained throughout the dietary intervention
period. The modest dietary changes of the WHI Dietary Modification
trial should be easily achievable by most postmenopausal women.
Study strengths include the randomized design, a population of
postmenopausal women, not selected for cognitive dysfunction, die-
tary program adherence supported by body weight and biomarker
differences [15] carefully designed and implemented procedures
Table 3
Randomized trials of dietary/multidomain interventions and cognition.
Name Eligibility N Intervention Duration Endpoint Outcome
FINGER Lance 2015t FINnish GERriatric
Intervention
Study to Prevent
Cognitive
Impairment and
Disability
6070 years old
Cardiovascular
Risk Factors Aging
and Dementia
score (CAIDE)  6
points
1260
46% Female
Diet, exercise, cogni-
tive training, vas-
cular risk
monitoring versus
control
2 years Neuropsychological
test battery (NTB)
Z score
NTB score higher in
Intervention
P = 0.030
MAPT Lancet Neu-
rology 2017
Multidomain Alz-
heimer
Prevention
Trial
70+ years old
1) Memory com-
plaints
2) Limitations in
ADL or
3) Slow gait
1525
65% Female
4 arms,
Multidomain (MD)
+placebo; Omega
3 FA alone; MD +
Omega 3 FA;
placebo
3 years Composite Z score
Combining 4 cog-
nitive tests
No significant effect
on cognitive
decline compared
to placebo
NU-AGE Diet
Frontier in Physi-
ology 2018
New dietary strate-
gies addressing
the specific needs
of the elderly pop-
ulation for
healthy ageing in
Europe
6779 years old
Free of dementia
relatively healthy
older adults
1279
100% Female
NU-AGE DIET,
Medi, like versus
usual diet control
1 year Cognitive function
Mini-Mental State
Examination
(MMSE)
Plus
CERAD score
No overall differ-
ence
Higher adheres
Improvement in
global function
PREDIMED-
NAVARRA
J Neurol Neuro-
surg Psychiatry
2013
Prevencion con
Dieta
Mediterranea
Age 75 years (mean)
High vascular risk
522
55% Female
3 arms,
2 MedDiets § extra-
virgin olive oil or
mixed nuts versus
“low fat” control**
6.5 years Mini-Mental State
Examination
(MMSE) plus
Clock Drawing
Test (CDT)
MedDiets higher
than control
MMSE, P = 0.005
CDT, P = 0.001
Item1 WHI statement
Will individual participant data be
available (including data
dictionaries)?
Deidentified individual participant data
is available.
What data in particular will be
shared?
All of the deidentified participant data
collected during the trial.
What other documents will be
available?
Study protocol, study procedures, data
collection forms and other documents.
When will data be available (start
and end dates)?
Data is available through the WHI online
resource, https://www.whi.org/
researchers/data/Pages/Home.aspx,
while the WHI remains funded2 and
indefinitely through BioLINCC, https://
biolincc.nhlbi.nih.gov/studies/whict/.
With whom? Eligible researchers3 may download the
data directly at the WHI online
resource. Other researchers may
download the publicly available data
through BioLINCC, in accordance with
NHLBI's BioLINCC guidelines.
For what types of analyses? Eligible researchers3 with an approved
specified purpose. Other researchers in
accordance with NHLBI's BioLINCC
guidelines.
By what mechanism will data be
made available?
Data are available at the aforementioned
links.
8 R.T. Chlebowski et al. / EClinicalMedicine 18 (2020) 100240assessing possible cognitive impairment, annual assessment of Global
cognitive function providing information on trajectory of cognitive
change, and a long follow-up period to support exploratory analyses
regarding implications for mortality.
Limitations include those associated with secondary analyses.
These analyses are exploratory and should be viewed as hypothesis-
generating, requiring reassessment in prospectively conducted con-
firmatory trials. While mild cognitive impairment or probable
dementia would have been a more meaningful endpoint, we were
limited by available sample size. The parent cohort, WHIMS
(n = 7479), was designed to have 80% power to detect an influence on
all-cause dementia. In addition, this study relied on the 3MSE, while
other instruments such as the Montreal Cognitive Assessment
(MoCA) [42] may better detect mild cognitive impairment. The WHI
low-fat dietary program reduced fat and commensurately increased
fruit, vegetable and grain consumption, therefore the effects of these
increases cannot be separated from the effects of reduced fat. Also,
social participation and support are strongly connected to good
health and well-being, so the sustained cognitive engagement by
nutritionist led intervention sessions could have had some positive
influence independent of dietary change. However, there is insuffi-
cient evidence regarding social activity and risk-reduction for risk of
cognitive decline. As linkage with Medicare provides more compre-
hensive assessment of dementia outcomes [43], a future analysis will
examine the low-fat dietary pattern influence on dementia incidence
and dementia mortality, in all 48,835 study participants.
As diabetes [44] and the metabolic syndrome have been associ-
ated with higher dementia risk [45], the favorable WHI dietary inter-
vention effects on the course of diabetes [41], hypertension [46],
other metabolic syndrome components [47] and weight manage-
ment [48], represent potential mediators of the cognitive effects
seen.
In summary, adoption of a low-fat dietary pattern, represent-
ing dietary moderation, significantly reduced risk of possible cog-
nitive impairment in postmenopausal women. Subsequent
mortality findings suggest the designation of possible cognitive
impairment likely identifies a higher risk population of clinical
relevance.Women’s Health Initiative (WHI) Data Sharing Statement:1Items correspond to those specified in: Taichman, D.B., Sahni, P.,
Pinborg, A., Peiperl, L., Laine, C., James, A., Hong, S.T., Haileamlak, A.,
Gollogly, L., Godlee, F. and Frizelle, F.A., 2017. Data sharing statements
for clinical trials: a requirement of the International Committee of Medi-
cal Journal Editors. Annals of internal medicine, 167(1), pp. 6365.
2Currently through 2020.
3See https://www.whi.org/researchers/data/Pages/Home.aspx for
eligibility.
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